DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies
Novartis
Novartis
Merck Sharp & Dohme LLC
St. Jude Children's Research Hospital
West China Hospital
AC Camargo Cancer Center